Article
Oncology
Zhuo-Xun Wu, Yuqi Yang, Leli Zeng, Harsh Patel, Letao Bo, Lusheng Lin, Zhe-Sheng Chen
Summary: Colorectal cancer is a leading cause of cancer-related deaths globally, with irinotecan commonly used as a chemotherapeutic drug. A new irinotecan-resistant colon cell line was established in this study, showing overexpression of ABC transporters as a potential mechanism of resistance. This research provides a novel in vitro model for studying irinotecan resistance and suggests targeting ABCG2 may help overcome drug resistance in colorectal cancer treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Jeanne Tie, Joshua D. Cohen, Kamel Lahouel, Serigne N. Lo, Yuxuan Wang, Suzanne Kosmider, Rachel Wong, Jeremy Shapiro, Margaret Lee, Sam Harris, Adnan Khattak, Matthew Burge, Marion Harris, James Lynam, Louise Nott, Fiona Day, Theresa Hayes, Sue-Anne McLachlan, Belinda Lee, Janine Ptak, Natalie Silliman, Lisa Dobbyn, Maria Popoli, Ralph Hruban, Anne Marie Lennon, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Cristian Tomasetti, Peter Gibbs
Summary: This study found that using ctDNA results to guide treatment decisions for stage II colon cancer reduced the use of adjuvant chemotherapy without compromising recurrence-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Meridith C. Ginesi, Jonathan T. Bliggenstorfer, Daphine M. Kwesiga, Samantha H. Xu, Diana Jodeh, J. Eva Selfridge, Sharon L. Stein, Emily F. Steinhagen
Summary: This study investigated the use of chemotherapy and its impact on survival in stage II colon cancer patients. It found that factors associated with not receiving chemotherapy in high-risk patients included increasing age, distance from the treatment facility, Charlson-Deyo score, and lack of insurance. Chemotherapy was associated with improved overall survival, but only high-risk patients benefited from it.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Nancy N. Baxter, Erin B. Kennedy, Emily Bergsland, Jordan Berlin, Thomas J. George, Sharlene Gill, Philip J. Gold, Alex Hantel, Lee Jones, Christopher Lieu, Najjia Mahmoud, Arden M. Morris, Erika Ruiz-Garcia, Y. Nancy You, Jeffrey A. Meyerhardt
Summary: The study aims to develop recommendations for adjuvant therapy for patients with resected stage II colon cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Xin Chen, Junhao Tu, Xiaolan Xu, Wen Gu, Lei Qin, Haixin Qian, Zhenyu Jia, Chuntao Ma, Yinkai Xu
Summary: This study found that adjuvant chemotherapy in elderly patients with stage III colon cancer can reduce cancer-specific mortality rate, but the benefit of chemotherapy in stage II colon cancer patients is suboptimal.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lana Khalil, Xingyu Gao, Jeffrey M. Switchenko, Olatunji B. Alese, Mehmet Akce, Christina Wu, Maria Diab, Bassel F. El-Rayes, Walid L. Shaib
Summary: This age group-based study examines the impact of adjuvant therapy in patients older than 70 with colon cancer. The study suggests that multi-agent chemotherapy may have better survival outcomes compared to single-agent chemotherapy in this age group.
Article
Oncology
Zhonglin Hao, Saurabh Parasramka, Quan Chen, Aasems Jacob, Bin Huang, Timothy Mullett, Al B. Benson
Summary: For resectable colon cancer with synchronous liver or lung metastasis, neoadjuvant chemotherapy before surgical resection of all lesions, especially in non-academic settings, has shown an overall survival advantage over adjuvant chemotherapy after surgery.
Article
Oncology
Qiangkang Lin, Huizhen Zhou, Si Shi, Jixu Lin, Wangxin Yan
Summary: The aim of this study was to investigate the survival benefit of adjuvant chemotherapy in patients with colon cancer with the solitary tumor deposit (TD). The study found that adjuvant chemotherapy administration significantly improved overall survival (OS) and colon cancer-specific survival (CSS) in these patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Brendan L. Hagerty, John G. Aversa, Dana A. Dominguez, Jeremy L. Davis, Jonathan M. Hernandez, James T. McCormick, Andrew M. Blakely
Summary: In patients with stage II colon cancer, young patients frequently receive adjuvant chemotherapy while older patients rarely receive adjuvant therapy. Age is an independent factor associated with the receipt of adjuvant chemotherapy.
DISEASES OF THE COLON & RECTUM
(2022)
Article
Surgery
Andrea M. Mesiti, Julianna Brouwer, Mehraneh D. Jafari, Yuqing Qiu, Lari Wenzel, Joseph Carmichael, Chelsea McKinney, Jason A. Zell, Alessio Pigazzi
Summary: This study aimed to assess the willingness of the general public to accept immediate adjuvant chemotherapy after surgery for colon cancer. The results showed that respondents with higher education were more likely to accept IAC for improved survival and quality of life, males were more likely to accept early termination of chemotherapy with possible side effects, and higher income respondents were more likely to accept early termination of chemotherapy without survival impact. Furthermore, 16% responded they would be very or extremely likely, and 52% respondents would be somewhat likely or likely to accept intraoperative chemotherapy, even if it may not be necessary.
JOURNAL OF SURGICAL RESEARCH
(2023)
Review
Oncology
Ester Oneda, Alberto Zaniboni
Summary: Adjuvant chemotherapy with FP plus oxaliplatin has shown to reduce disease recurrence risk and mortality in resected MSI RCRC. The standard treatment is effective, but can be avoided in low-risk stage II patients. Immunotherapy is being considered as a potential alternative in the adjuvant setting.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Oncology
Xiaohong Han, Zheng Wang, Lei Zhang, Yinchen Shen, Qiaoyun Tan, Yongkun Sun, Jianfei Wang, Xiaoyan Qian, Hongying Yang, Yuankai Shi
Summary: A three-stage study framework identified a stable association of rs6891545C > A polymorphism in the SLF1 gene with the response to oxaliplatin-based adjuvant chemotherapy in patients with stage II and III colon cancer, suggesting that patients carrying the A allele had better treatment response.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Yuka Ahiko, Dai Shida, Yozo Kudose, Yuya Nakamura, Konosuke Moritani, Shinichi Yamauchi, Kenichi Sugihara, Yukihide Kanemitsu
Summary: This study compared the recurrence hazard of stage III rectal cancer with that of colon cancer by adjuvant chemotherapy status using the hazard function. The results showed that adjuvant chemotherapy delayed the peak of recurrence and suppressed distant recurrence in rectal cancer patients, similar to what is observed in colon cancer patients.
JOURNAL OF GASTROENTEROLOGY
(2021)
Editorial Material
Medicine, General & Internal
Clara Montagut, Joana Vidal
Summary: Liquid biopsy, the detection of tumor-related DNA in the peripheral blood, is a promising tool for predicting the benefit of targeted drugs and assessing residual disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Surgery
Richard J. Straker, Danny H. J. Heo, Adrienne B. Shannon, Douglas L. Fraker, Skandan Shanmugan, Charles J. Schneider, Najjia N. Mahmoud, John T. Miura, Giorgos C. Karakousis
Summary: A predictive risk-score model can identify a high-risk cohort of stage II colon cancer patients who are most likely to benefit from adjuvant systemic therapy.
Article
Oncology
Marc Ychou, Michel Rivoire, Simon Thezenas, Rosine Guimbaud, Francois Ghiringhelli, Anne Mercier-Blas, Laurent Mineur, Eric Francois, Faiza Khemissa, Marion Chauvenet, Reza Kianmanesh, Marianne Fonck, Philippe Houyau, Thomas Aparicio, Marie-Pierre Galais, Franck Audemar, Eric Assenat, Evelyne Lopez-Crapez, Claire Jouffroy, Antoine Adenis, Rene Adam, Olivier Bouche
Summary: The study found that in CRC patients initially deemed unresectable, there was no significant increase in R0/R1 liver-resection rate by using 3-CTx combined with bevacizumab or cetuximab based on RAS status.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Caroline Touloupas, Matthieu Faron, Julien Hadoux, Frederic Deschamps, Charles Roux, Maxime Ronot, Steven Yevich, Julien Joskin, Maximiliano Gelli, Remy Barbe, Livia Lamartina, Hubert Tissot, Jean-Yves Scoazec, David Malka, Michel Ducreux, Eric Baudin, Thierry de Baere, Lambros Tselikas
Summary: Treating NET liver metastases with TACE has shown long-term efficacy and survival rates, with imaging responses correlating significantly with overall survival. This study confirms the effectiveness of TACE and the importance of imaging evaluation in tailoring patient treatment.
Article
Oncology
Jean-Luc Raoul, Julien Edeline, Victor Simmet, Camille Moreau-Bachelard, Marine Gilabert, Jean-Sebastien Frenel
Summary: Multikinase inhibitors and immune checkpoint inhibitors are major breakthroughs in cancer treatment, but the overuse of proton pump inhibitors may have detrimental effects on cancer patients' therapy and decrease the absorption of targeted therapies. Furthermore, long-term use of proton pump inhibitors alters the gut microbiome and suppresses the benefit of using immune checkpoint inhibitors.
Review
Endocrinology & Metabolism
Jaume Capdevila, Michel Ducreux, Rocio Garcia Carbonero, Enrique Grande, Thorvardur Halfdanarson, Marianne Pavel, Salvatore Tafuto, Staffan Welin, Vicente Valenti, Ramon Salazar
Summary: This review provides a historical perspective on the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). It discusses the chemical structure, pharmacokinetics, and mechanism of action of streptozotocin, and presents data from prospective and retrospective clinical studies. The review also highlights the latest developments and future prospects for the use of streptozotocin in panNET treatment.
NEUROENDOCRINOLOGY
(2022)
Article
Oncology
Zhenggang Ren, Michel Ducreux, Ghassan K. Abou-Alfa, Philippe Merle, Weijia Fang, Julien Edeline, Zhiwei Li, Lihua Wu, Eric Assenat, Sheng Hu, Lorenza Rimassa, Tao Zhang, Jean-Frederic Blanc, Hongming Pan, Paul Ross, Chia-Jui Yen, Albert Tran, Guoliang Shao, Mohamed Bouattour, Yajin Chen, Tim Meyer, Jinlin Hou, David Tougeron, Yuxian Bai, Ming-Mo Hou, Zhiqiang Meng, John Wu, Vincent Li, Sandra Chica-Duque, Ann-Lii Cheng
Summary: Tislelizumab demonstrated durable antitumor activity and acceptable tolerability in previously treated advanced HCC patients, regardless of the number of prior lines of therapy.
Article
Oncology
Chiun Hsu, Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Peter R. Galle, Richard S. Finn, Ethan Chen, Ning Ma, Youyou Hu, Lindong Li, Ann-Lii Cheng
Summary: The IMbrave150 trial showed that atezolizumab + bevacizumab is safe and effective in treating patients with hepatocellular carcinoma, including those with hepatitis B or hepatitis C infection.
Article
Oncology
Camille Moreau-Bachelard, Valentin Letailleur, Emmanuelle Bompas, Patrick Soulie, Julie Paul, Jean-Luc Raoul
Summary: This study retrospectively investigated the impact of combining proton pump inhibitors (PPIs) with pazopanib on the clinical efficacy and safety. The results showed that combining PPIs with pazopanib led to lower efficacy and decreased overall survival. The combination was associated with performance status, tumor location, hemoglobin level, and PMN/lymphocyte ratio. Dose reduction for toxicity and severe adverse events were less frequent in the combination group. Hence, the co-medication should be avoided.
Article
Oncology
Masatoshi Kudo, Richard S. S. Finn, Peter R. R. Galle, Andrew X. X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni
Summary: The study demonstrates the efficacy and safety of atezolizumab + bevacizumab treatment in patients with baseline BCLC Stage B hepatocellular carcinoma, consistent with the overall study population.
Review
Oncology
Julien Edeline, Tim Meyer, Jean-Frederic Blanc, Jean-Luc Raoul
Summary: This review summarizes the data on a new treatment for hepatocellular carcinoma. Immunotherapy-based combination therapies have emerged as effective treatment options. The article discusses the challenges in selecting the most appropriate treatment, options after failure of these new treatments, and the future of drug development in advanced HCC.
Article
Oncology
Valerie Seegers, Guillaume Rousseau, Ke Zhou, Audrey Blanc-Lapierre, Frederic Bigot, Hakim Mahammedi, Aurelien Lambert, Camille Moreau-Bachelard, Mario Campone, Thierry Conroy, Frederique Penault-Llorca, Michele Boisdron-Celle, Martine Bellanger, Jean-Luc Raoul
Summary: This study demonstrates the importance of two doses of COVID-19 vaccines for cancer patients and healthcare workers. Despite a decline in post-vaccination antibody levels and some vaccine breakthrough infections, the vaccination was still effective for both populations studied.
Article
Medicine, General & Internal
Margaux Lelong, Jean-Luc Raoul, Yann Touchefeu, Jean-Marie Berthelot, Paul Arnolfo, Tamara Matysiak-Budnik, Helene Senellart
Summary: A 38-year-old man with a familial BRCA2 mutation presented with symptoms including skin erythema, polyarthritis, dactylitis, and febrile erythema nodosum. A biopsy of a liver metastasis revealed acinar cell carcinoma of the pancreas. After receiving FOLFIRINOX treatment followed by olaparib, the patient achieved a PS of 0 and became asymptomatic after 24 months.
CLINICAL CASE REPORTS
(2022)
Article
Oncology
Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
Summary: This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab + bevacizumab or sorafenib. The study found that atezolizumab + bevacizumab improved overall survival and progression-free survival compared to sorafenib in patients with ALBI score of 1, but not in patients with ALBI score of 2. ALBI grade appeared to be prognostic for outcomes in both treatment groups.
Review
Oncology
Raefa Abou Khouzam, Jean-Marie Lehn, Hemma Mayr, Pierre-Alain Clavien, Michael Bradley Wallace, Michel Ducreux, Perparim Limani, Salem Chouaib
Summary: Hypoxia is a crucial characteristic of the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) and plays a significant role in its pathogenesis. This review focuses on the impact of hypoxia on genomic instability and the tumor immune microenvironment in PDAC. Strategies for alleviating hypoxia and their potential applications for diagnosis and therapy in PDAC patients will also be discussed.
Article
Oncology
Paul Matte, Michel Ducreux
Summary: This article reports a case of a patient with low rectal cancer who experienced vision loss 3 weeks after starting treatment with capecitabine and radiotherapy. After ruling out other possible diagnoses, toxicity of the antineoplastic agent is considered the most likely hypothesis, making it the first case of vision loss induced by capecitabine.
CASE REPORTS IN ONCOLOGY
(2023)
Article
Oncology
Ke Zhou, Jean-Luc Raoul, Audrey Blanc-Lapierre, Valerie Seegers, Michele Boisdron-Celle, Marianne Bourdon, Hakim Mahammedi, Aurelien Lambert, Camille Moreau-Bachelard, Mario Campone, Thierry Conroy, Frederique Penault-Llorca, Martine M. Bellanger, Frederic Bigot
Summary: The COVID-19 infection rate in cancer patients is similar to that in healthcare workers, but the mortality rate related to clinical symptoms is lower. More than 40% of COVID (+) cancer patients are asymptomatic, while one-third of COVID (-) cancer patients have symptoms. Only geographic origin is associated with clinical presentation.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY
(2022)